Elastin-like Polypeptide Fusion Proteins for Ocular Drug Retention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug delivery methods for treating eye disorders, such as dry eye syndrome, face challenges due to rapid clearance of medications from the eye, resulting in low bioavailability and the need for frequent administration, which limits the effectiveness and convenience of protein-based therapies.
Innovation Solution
Development of temperature-sensitive protein polymers, specifically elastin-like polypeptides (ELPs), are fused with therapeutic proteins like lacritin to create fusion proteins that retain drugs on the eye surface for extended periods, utilizing phase transition behavior to slow clearance and enhance ocular retention.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If conventional eye drops containing small molecule drugs or recombinant tear proteins are used, then the treatment can be administered topically, but the drugs are rapidly washed away from the eye within minutes resulting in less than 2% absorption
Solution Approach 1:
The invention creates a fusion protein composite by combining elastin-like polypeptide (ELP) with therapeutic proteins (e.g., lacritin). The ELP component provides ocular retention properties while the therapeutic protein provides biological activity. This composite structure allows the drug to resist tear wash clearance and remain on the ocular surface for extended periods (days to weeks), dramatically improving absorption from less than 2% to significantly higher levels while maintaining ease of topical administration.
Solution Approach 2:
The elastin-like polypeptide component undergoes temperature-dependent conformational changes that affect its interaction with the ocular surface. The ELP transitions from a disordered state at lower temperatures to an ordered, aggregate-prone state at physiological temperatures (above its transition temperature), which enhances its ability to retain the therapeutic protein on the eye surface. This parameter change (temperature response) directly improves drug retention and absorption.
2Quantity of substance
If conventional eye drops are administered frequently to maintain therapeutic levels, then drug absorption can be improved, but the treatment frequency increases and convenience decreases
Solution Approach 1:
The ELP-therapeutic protein fusion creates a composite material with inherently prolonged ocular residence time. The ELP component's unique properties (temperature sensitivity, aggregate formation) cause the fusion protein to adhere to the ocular surface and resist tear wash clearance. This single administration delivers therapeutic levels of the drug over days to weeks, eliminating the need for frequent re-dosing and maintaining both high absorption and ease of operation.
Solution Approach 2:
The fusion protein is designed to over-deliver or persist on the ocular surface beyond the typical residence time of conventional eye drops. By engineering the ELP component with specific transition temperatures and aggregate-forming properties, the drug remains retained at therapeutic concentrations for an extended period (excessive action compared to conventional drops), allowing single or infrequent administrations to achieve cumulative absorption equivalent to multiple daily doses.
3Reliability
If protein-based drugs are used to treat dry eye syndrome, then therapeutic efficacy can be improved, but the drugs are rapidly cleared from the eye preventing effective delivery
Solution Approach 1:
The invention creates a fusion protein composite where elastin-like polypeptide (ELP) is genetically fused to therapeutic proteins such as lacritin. The ELP component provides prolonged ocular retention through temperature-dependent aggregation and adhesion to the ocular surface, while the therapeutic protein component maintains full biological activity. This composite structure simultaneously achieves both high drug retention (resisting tear wash clearance for days to weeks) and reliable therapeutic efficacy.
Solution Approach 2:
The elastin-like polypeptide acts as an intermediary carrier that mediates between the therapeutic protein and the ocular surface environment. The ELP's temperature-sensitive conformational changes and aggregate formation capability create a protective interface that shields the therapeutic protein from rapid clearance by tears while allowing it to maintain its biological function. This intermediary role enables both extended retention and reliable efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The fusion proteins demonstrate improved retention and bioavailability of therapeutic proteins on the eye surface, extending treatment duration from days to weeks, reducing the frequency of administration and enhancing therapeutic efficacy while maintaining biocompatibility.
Implementation Method 1
utilizing phase transition behavior to slow clearance and enhance ocular retention
Data Source
AI summary
Described herein are bioresponsive protein polymers for therapeutic applications, including delivery to physiologically demanding environments, such as the eye surface. Bioresponsive protein polymers can be fused with biopharmaceuticals using genetic engineering techniques for enhanced therapeutic activity. In certain embodiments, the unique temperature-sensitive phase separation properties of bioresponsive protein polymers, allows generation of therapeutics resistant to ocular clearance. Such fusion proteins containing bioresponsive protein polymers and biopharmaceuticals allow retention of drugs in the eye for much longer periods of time. Improved biostability and bioavailability improves drug efficacy, while reducing cost and eliminating the need for repeated drug Application.